HC Wainwright & Co. Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $82
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on Apellis Pharmaceuticals (NASDAQ:APLS) but has lowered the price target from $100 to $82.
July 21, 2023 | 10:19 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Despite the lowered price target, HC Wainwright & Co. maintains a 'Buy' rating on Apellis Pharmaceuticals, indicating continued confidence in the company's prospects.
The lowered price target may initially cause some investor concern, potentially leading to short-term price volatility. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company, which could balance out any negative impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100